Critical appraisal of trastuzumab in treatment of advanced stomach cancer

Cancer Management and Research

Volumn 3, Issue 1, 2011, Pages 57-64

  Meza Junco, Judith ^a   Au, Heather Jane ^a   Sawyer, Michael B ^a  

^a CROSS CANCER INSTITUTE   (Canada)

Author keywords

Gastric cancer; HER 2; Trastuzumab

Indexed keywords

AP 24534; BCR ABL PROTEIN; BOSUTINIB; DASATINIB; HOMOHARRINGTONINE; IMATINIB; NILOTINIB; PROTEIN KINASE LYN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANEMIA; ARTHRALGIA; BINDING AFFINITY; BIOCHEMISTRY; BONE MARROW SUPPRESSION; BONE PAIN; CANCER SURVIVAL; CARDIOTOXICITY; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; CONGESTIVE HEART FAILURE; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG MONITORING; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ENZYME ACTIVATION; ENZYME BINDING; ENZYME INHIBITION; EVENT FREE SURVIVAL; FATIGUE; FLUID RETENTION; HEART LEFT VENTRICLE FAILURE; HEMATOLOGIC DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; LEUKEMIA REMISSION; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREATITIS; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PHILADELPHIA 1 CHROMOSOME; PLEURA EFFUSION; POINT MUTATION; PROGRESSION FREE SURVIVAL; PRURITUS; QT PROLONGATION; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIDE EFFECT; STRUCTURE ANALYSIS; SUDDEN DEATH; THROMBOCYTOPENIA; VOMITING; WEIGHT GAIN;

EID: 79952904409     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMR.S12698     Document Type: Review

References (76)

1. American Cancer Society. Cancer Facts and Figures 2010. Atlanta, GA: American Cancer Society; 2010.
2. Sugano K. Gastric cancer: Pathogenesis, screening, and treatment. Gastrointest Endosc Clin N Am. 2008;18(3):513-522.
3. Inoue M, Tsugane S. Epidemiology of gastric cancer in Japan. Postgrad Med J. 2005;81(957):419-424.
4. Foukakis T, Lundell L, Gubanski M, et al. Advances in the treatment of patients with gastric adenocarcinoma. Acta Oncol. 2007;46(3):277-285.
5. Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993;72(1):37-41.
6. Pyrhönen S, Kuitunen T, Nyandoto P, et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71(1):587-591.
7. Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8(2):163-168.
8. Janunger KG, Hafström L, Glimelius B. Chemotherapy in gastric cancer: A review and updated meta-analysis. Eur J Surg. 2002;168(11):597-608.
9. Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903-2909.
10. Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002;20(8):1996-2004.
11. Cunningham D, Starling N, Rao S, et al; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36-46.
12. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A Report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991-4997.
13. Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: The V-325 Study Group. J Clin Oncol. 2007;25(22):3205-3209.
14. Bouche O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: A Federation Francophone de Cancerologie Digestive Group Study - FFCD 9803. J Clin Oncol. 2004;22(21):4319-4328.
15. Moehler M, Eimermacher A, Siebler J, et al. Randomized phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) versus 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer. 2005;92(12):2122-2128.
16. Dank M, Zaluski J, Valvere V, et al. Randomized phase III trial of irinotecan (CPT 11) 5-FU/folinic acid (FA) vs CDDP-5-FU in first line advanced gastric cancer patients. J Clin Oncol. 2005;23 Suppl 16: S4003.
17. Boku N, Yamamoto S, Shirao K, et al. Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). J Clin Oncol. 2007;25 Suppl 18:SLBA4513T.
18. Imamura H, IIishi H, Tsuburaya A, et al. Randomized phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer (GC0301/TOP-002). Poster A5 presented at the ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, January 15-17, 2008.
19. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol. 2008;9(3):215-221.
20. Wagner AD, Unerzagt S, Grothe W, et al. Novel chemotherapy combinations in advanced gastric cancer: An updated meta-analysis. Ann Oncol. 2010;21 Suppl 8:S740.
21. Guimbaud R, Louvet C, Bonnetain F, et al. Final results of the intergroup FFCD-GERCOR-FNCLCC 03-07 phase III study comparing two sequences of chemotherapy in advanced gastric cancers. Ann Oncol. 2010;21 Suppl 8:S8010.
22. Thuss-Patience PC, Kretzschmar A, Deist T, et al. Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: A randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol. 2009;27 Suppl 5:S4540.
23. Shimoyama R, Yasui H, Boku N, et al. Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin. Gastric Cancer. 2009;12(4):206-211.
24. Takahari D, Shimada Y, Takeshita S, et al. Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer. Gastric Cancer. 2010;13(3):186-190.
25. Wilson D, Hiller L, Geh JI. Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol (R Coll Radiol). 2005;17(2):81-90.
26. Boku N. Chemotherapy for metastatic gastric cancer in Japan. Int J Clin Oncol. 2008;13(6):483-487.
27. Bang YJ, Kang YK, Kang WK, et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs. 2010 May 12. [Epub ahead of print].
28. Yoon DH, Ryu1 M, Lee J, et al. Phase II study of everolimus in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Ann Oncol. 2010;21 Suppl 8:S725.
29. Tebbutt NC, Sourjina T, Strickland AH, et al. ATTAX2: Docetaxel plus cetuximab as second-line treatment for docetaxel refractory oesophago-gastric cancer - final results of a multicentre phase II trial by the AGITG. J Clin Oncol. 2008;26 Suppl 20:S15554.
30. Arkenau HT. Gastric cancer in the era of molecularly targeted agents: current drug development strategies. J Cancer Res Clin Oncol. 2009;135(2):855-866.
31. Ohtsu A. Chemotherapy for metastatic gastric cancer: Past, present, and future. J Gastroenterol. 2008;43(4):256-264.
32. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006;24(33):5201-5206.
33. Enzinger PC, Fidias P, Meyerhardt J, et al. Phase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer. Poster A68 presented at the ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, January 26-28, 2006.
34. Cohenuram MK, Lacy J. FOLFOX6 and bevacizumab (FOLFOX6/B) for metastatic esophageal (E), gastroesophageal (GE), and gastric (G) adenocarcinoma: A single institution's initial clinical experience. Poster A74 presented at the ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, January 15-17, 2008.
35. Hammad N, Philip PA, Shields AF, et al. A phase II study of bevacizumab, docetaxel, and oxaliplatin in gastric and gastroesophageal junction (GEJ) cancer. Poster A30 presented at the ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, January 15-17, 2008.
36. Bang YJ, Kang Y, Kang W, et al. Sunitinib as second line treatment for advanced gastric cancer: Preliminary results from a phase II study. J Clin Oncol. 2007;25 Suppl 18:S4603.
37. Park SR, Lee K, Oh D, et al. Sunitinib (su) with cisplatin (p) and capecitabine (x) or oxaliplatin (o) and x (xelox) in advanced gastric cancer (gc) - a phase I, dose-finding study. Ann Oncol. 2010;21 Suppl 8: S815.
38. K, Miyata Y, Li M, Watanabe K, Boku N. Cisplatin (P) in patients (pts) with advanced or metastatic gastric cancer (CG). Ann Oncol. 2010;21 Suppl 8:S816.
39. C, Gil-Martin M, Montagut C. A phase I, dose-finding study of sunitinib (su) in combination with cisplatin (p) and 5-fluorouracil (5-fu) in patients (pts) with advanced gastric cancer (gc). Ann Oncol. 2010;21 Suppl 8:S818.
40. Sun W, Powell ME, O'Dwyer P, et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol. 2010:28(18):2947-2951.
41. Stein A, Al-Batran SE, Arnold D, et al. Cetuximab with irinotecan as salvage therapy in heavily pretreated patients with metastatic gastric cancer. Poster A47 presented at the ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, January 15-17, 2008.
42. Pinto C, Di Fabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol. 2007;18(3):510-517.
43. Lordick F, Luber B, Lorenzen S, et al. Cetuximab plus oxaliplatin/ leucovorin/5-fluorouracil in first-line metastatic gastric cancer: A phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer. 2010;102(3):500-505.
44. Kim C, Lee JL, Ryu MH, et al. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest New Drugs. 2009 December 9. [Epub ahead of print].
45. Pinto C, Di Fabio F, Barone C, et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer. 2009;101(8):1261-1268.
46. Rao S, Starling N, Cunningham D, et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: A randomised, multicentre open-label phase II study. Ann Oncol. 2010;21(11):2213-2219.
47. Dragovich T, McCoy S, Fenoglio-Preiser C, et al. SWOG 0127 phase II trial of erlotinib in GEJ and gastric adenocarcinoma. J Clin Oncol. 2006;24(30):4922-4927.
48. Doi T, Koizumi W, Siena S, et al. Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer. Proc Am Soc Clin Oncol. 2003;22:Abstr 1036.
49. Iqbal S, Goldman B, Lenz HJ, et al. A phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer. J Clin Oncol. 2007;25 Suppl 8: S4621.
50. Lenz H, Zhang W, Kemner AM. Lapatinib 1 capecitabine in advanced gastric cancer: An open-label phase II study of non ERBB2-targeted disease. Ann Oncol. 2010;21 Suppl 8:S817.
51. Okines AF, Ashley SE, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: Dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol. 2010;28(25):3945-3950.
52. Rao S, Starling N, Cunningham D, et al. Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br J Cancer. 2008;99(6):868-874.
53. Baselga J, Swain SM. Novel anticancer targets: Revisiting ERBB2 and discovering ERB3. Nat Rev Cancer. 2009;9(7):463-475.
54. Halla PS, Cameron DA. Current perspective - trastuzumab. Eur J Cancer. 2009;45(1):12-18.
55. Carter P, Presta L, Gorman CM, et al. Humanization of an antip185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 1992;89(10):4285-4289.
56. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 2007;18(6):977-984.
57. Treish I, Schwartz R, Lindley C. Pharmacology and therapeutic use of trastuzumab in breast cancer. Am J Health Syst Pharm. 2000;57(22):2063-2076.
58. Bruno R, Washington CB, Lu JF, et al. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol. 2005;56(4):361-369.
59. Marx AH, Tharun L, Muth J, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol. 2009;40(6):769-777.
60. Barros-Silva JD, Leitão D, Afonso L, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer. 2009;100(3):487-493.
61. Kim MA, Jung EJ, Lee HS, et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol. 2007;38(9):1386-1393.
62. Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: Association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005:16(2):273-278.
63. Yano T, Doi T, Ohtsu A, et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep. 2006;15(1):65-71.
64. Yu GZ, Chen Y, Wang JJ. Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol. 2009;135(10):1331-1339.
65. Bang Y, Chung H, Xu J, et al. Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol. 2009;27 Suppl 15:S4556.
66. Gong SJ, Jin CJ, Rha SY, et al. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Lett. 2004;214(2):215-224.
67. Cortés-Funes H, Rivera F, Alés I, et al. Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/ neu overexpression/amplification. J Clin Oncol. 2007;25 Suppl 18: S4613.
68. Egamberdiev DM, Djuraev MD, Tuydjanova K, Nematov ON. Our experience in the use of trastuzumab in patients with advanced stomach cancer. Ann Oncol. 2010;21 Suppl 8:S839.
69. Van Cutsem E, Kang Y, Chung H, et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomized controlled trial. Lancet. 2010;376(9742):687-697.
70. Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39-51.
71. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215-1221.
72. González V, Salgueiro E, Jimeno FJ, et al. Post-marketing safety of antineoplasic MAb: Rituximab and trastuzumab. Pharmacoepidemiol Drug Saf. 2008;17(7):714-721.
73. Osoba D, Slamon DJ, Burchmore M, Murphy M. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol. 2002;20(14): 3106-3113.
74. Rugo H, Brammer M, Zhang F, Lalla D. Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: Data from three clinical trials. Clin Breast Cancer. 2010;10(4):288-293.
75. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;112(3):533-543.
76. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. New Engl J Med. 2006;355(26):2733-2743.